We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

71 hedge funds and large institutions have $202M invested in AEON Biopharma in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $192M → $202M (+$10.3M)

0.05% more ownership

Funds ownership: 0.99% → 1.04% (+0.05%)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

3% less funds holding

Funds holding: 73 → 71 (-2)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

Holders
71
Holders Change
-2
Holders Change %
-2.74%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
12
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$9.74M
2
SC
Sculptor Capital
New York
+$4.67M
3
SCM
Saba Capital Management
New York
+$4.21M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.47M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$2.34M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$4.99M
2
Blackstone Inc
Blackstone Inc
New York
-$4.48M
3
Wells Fargo
Wells Fargo
California
-$2.76M
4
MP
Mangrove Partners
Connecticut
-$2.06M
5
ACA
Arena Capital Advisors
California
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
ECP
1
Empyrean Capital Partners
California
$13.7M – – –
Marshall Wace
2
Marshall Wace
United Kingdom
$13M – – –
DKCM
3
Davidson Kempner Capital Management
New York
$12.4M – – –
HSBC Holdings
4
HSBC Holdings
United Kingdom
$10.8M – – –
Citadel Advisors
5
Citadel Advisors
Florida
$10.8M -$12.6K -18 -0.1%
AC
6
Aristeia Capital
Connecticut
$9.78M +$9.74M +13,889 New
RCM
7
Radcliffe Capital Management
Pennsylvania
$8.48M – – –
SCM
8
Shaolin Capital Management
Florida
$7.92M – – –
PC
9
Periscope Capital
Ontario, Canada
$7.54M +$160K +228 +2%
LA
10
Linden Advisors
New York
$5.87M – – –
LP
11
LMR Partners
United Kingdom
$5.87M – – –
Millennium Management
12
Millennium Management
New York
$5.56M -$108K -154 -2%
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$5.49M +$3.47M +4,947 +173%
Hudson Bay Capital Management
14
Hudson Bay Capital Management
Connecticut
$5.29M – – –
SCM
15
Saba Capital Management
New York
$5.08M +$4.21M +6,004 +497%
CH
16
CVI Holdings
Delaware
$5.04M +$148K +211 +3%
FTCM
17
Fir Tree Capital Management
New York
$4.95M – – –
TCM
18
Tenor Capital Management
New York
$4.89M – – –
KIM
19
Karpus Investment Management
New York
$4.76M – – –
SC
20
Sculptor Capital
New York
$4.69M +$4.67M +6,656 New
PMAM
21
Picton Mahoney Asset Management
Ontario, Canada
$3.42M – – –
WA
22
Whitebox Advisors
Minnesota
$2.94M -$210K -300 -7%
State of Wisconsin Investment Board
23
State of Wisconsin Investment Board
Wisconsin
$2.81M +$360K +513 +15%
Goldman Sachs
24
Goldman Sachs
New York
$2.71M – – –
CCA
25
Castle Creek Arbitrage
Colorado
$2.5M – – –
1
2 3 4

AEON Hedge Fund Activity: Q1 2022 in Review

71 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2022, worth a combined $202M — up 5.4% from $192M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of AEON and 8 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 12 added.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $9.74M. The largest seller was UBS O'Connor, exiting entirely with an estimated $4.99M sold.

  • 71 institutional investors held AEON Biopharma (AEON) as of Q1 2022, down from 73 in Q4 2021.
  • Funds reported $202M of AEON Biopharma stock for Q1 2022, up 5.4% quarter-over-quarter.
  • 8 funds opened new AEON Biopharma positions in Q1 2022 and 10 closed out, a net change of -2 holders.
  • The largest AEON Biopharma buyer in Q1 2022 was Aristeia Capital, an estimated $9.74M added.
  • The largest AEON Biopharma seller in Q1 2022 was UBS O'Connor, an estimated $4.99M sold.

Based on aggregated 13F filings for Q1 2022.